Thomas Beyer

Kiel University — Germany

Medicine · Health Sciences

18h-index1.5kcitations37works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(20), Glycosylation and Glycoproteins Research(12), T-cell and B-cell Immunology(7), Phagocytosis and Immune Regulation(7), HER2/EGFR in Cancer Research(6)

Publications37 total

Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2 m(1) antibody
mAbs·2013· 19 citedOpen Access
The role of epidermal growth factor receptor (EGFR)-directed recombinant dimeric IgA antibodies in tumor cell killing.
Journal of Clinical Oncology·2011
Recombinant Dimeric IgA Antibodies against the Epidermal Growth Factor Receptor Mediate Effective Tumor Cell Killing
The Journal of Immunology·2011· 66 citedOpen Access
Recombinant Dimeric IgA Antibodies as Tumor-Specific Agents.
Blood·2010
Impact of Human IgA Antibodies on Complement-Dependent Cytotoxicity Mediated by Combinations of EGF-R-Directed Antibodies
Archivum Immunologiae et Therapiae Experimentalis·2010· 7 cited
Expression of IgA Molecules in Mammalian Cells
2010· 1 cited
Granzyme B-secreting B cells suppress CD4(+) T cell expansion
Naunyn-Schmiedeberg s Archives of Pharmacology·2010
Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage
The Journal of Immunology·2009· 216 citedOpen Access
Effect of the epidermal growth factor receptor antibody panitumumab on triggering of ADCC
Journal of Clinical Oncology·2009· 2 cited
Serum-free production and purification of chimeric IgA antibodies
Journal of Immunological Methods·2009· 49 cited
and PMN effector cells Antibody fucosylation differentially impacts cytotoxicity mediated by NK
2009
Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
Cancer Research·2008· 162 cited
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells
Blood·2008· 215 citedOpen Access
Tumor Cell Killing Mechanisms of Epidermal Growth Factor Receptor (EGFR) Antibodies Are Not Affected by Lung Cancer-Associated EGFR Kinase Mutations
The Journal of Immunology·2008· 24 citedOpen Access
Recombinant Chimeric IgA1 and IgA2 Antibodies for Tumor Immunotherapy.
Blood·2007
Effector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor
The Journal of Immunology·2007· 89 citedOpen Access
Lung cancer-derived EGFR mutations affect responses to tyrosine kinase inhibitors, but not to monoclonal antibodies
Journal of Clinical Oncology·2007
Molecular Engineering III: Fc Engineering
2007· 4 cited
Impact of antibody Fc carbohydrate fucosylation on antibody-dependent cellular cytotoxicity by HuMax-EGFr —A fully human epidermal growth factor receptor antibody
Journal of Clinical Oncology·2006· 3 citedOpen Access
Fully Human CD38 Antibodies Efficiently Trigger ADCC of Multiple Myeloma Cell Lines and Primary Tumor Cells.
Blood·2005· 1 cited
page 1 of 2Next →

Frequent Co-authors

Thomas Valerius(20), Michael Dechant(18), Matthias Peipp(17), Martin Herrmann(14), Jan G. J. van de Winkel(10), Reinhard Voll(10), Tanja Schneider‐Merck(9), Stefan Lohse(9), Paul W.H.I. Parren(9), Udo S. Gaipl(9), Jeroen J. Lammerts van Bueren(7), Joachim R. Kalden(7), Sven Berger(5), Stefanie Derer(5), Wim K. Bleeker(5), Wasilis Kolowos(5), Petra Heyder(5), Roland Repp(4), Susanne Kuenkele(4), J. R. Kalden(4)